Services Valuation: Multiples, Payer Mix, Same-Store Growth, and De Novo Economics

Introduction

Valuation in healthcare services is driven by a different set of factors than in pharma (where patent portfolios and pipeline rNPVs dominate) or MedTech (where organic growth and revenue quality drive premium). In services, three factors explain the majority of multiple dispersion: payer mix, same-store growth, and sub-sector positioning. Healthcare bankers who can articulate why a dermatology platform trades at 14x while a primary care platform trades at 8x will outperform those who simply quote "healthcare services multiples."

Payer mix is the single most powerful multiple driver in healthcare services valuation. The mechanism is straightforward: commercial payers reimburse at 150-300% of Medicare rates, so practices with higher commercial payer mix generate more revenue per encounter, have higher margins, and face less reimbursement risk from government payer policy changes.

Payer Mix Premium

The valuation premium applied to healthcare services companies with a high proportion of commercial (private insurance) payer revenue relative to government payer (Medicare, Medicaid) revenue. A practice with 70% commercial payer mix might trade at 12-14x EBITDA, while a clinically similar practice with 70% Medicaid payer mix might trade at 6-8x. The premium reflects three compounding effects: (1) higher revenue per encounter, (2) higher EBITDA margins (from the revenue uplift), and (3) lower reimbursement risk (commercial rates are negotiated bilaterally, not set by government fiat). The premium compounds because revenue, margin, and multiple are all higher, making payer mix the most leveraged variable in healthcare services valuation.

Same-store growth (also called organic growth or comparable-location growth) measures revenue or volume growth at locations that have been in operation for at least 12 months, excluding acquisitions and de novo openings from the calculation.

Why it matters: In a sector where most growth comes from add-on acquisitions, same-store growth separates platforms with genuine organic momentum from those growing only through M&A. A platform reporting 25% total revenue growth but only 2% same-store growth is growing almost entirely through acquisitions, raising questions about what happens if the acquisition pipeline slows.

Benchmarks: Same-store growth of 3-5% is considered healthy across most sub-sectors. Above 5% signals strong organic demand and effective operational execution. Below 2% suggests the platform may be struggling to grow its existing locations, which could indicate competitive pressure, provider turnover, or payer mix deterioration.

De novo expansion (opening new locations organically) is increasingly valued by investors because it demonstrates the platform's ability to grow without paying acquisition premiums.

De novo locations that reach maturity contribute EBITDA at the platform's exit multiple without the acquisition premium embedded in add-on deals. A de novo that cost $500K to open and generates $300K in mature EBITDA is worth $3-4.5M at exit (10-15x multiple), a 6-9x return on invested capital.

The next article covers labor costs and the healthcare staffing crisis, the single largest risk factor for healthcare services margins.